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Abstracts 
One hundred and fifteen patients underwent 
orthotopic liver transplantation (OL T) for primary liver 
malignancy. Overall survivals of these patients were signifi-
cantly lower than those of patients with non-malignant dis-
eases (5-year survival rates 37 % and 65 %, respectively). 
Hepatocellular carcinoma (RCC) was the most common 
malignancy among our patients (n = 80). Fibrolamellar 
HCC (n = 9) was associated with better survival than non-
fibrolamellar HCC (N = 71) among the lesions 2: 5 cm in 
diameter. More frequent recurrence was noted in patients 
with large tumors (2: 5 cm), multiple tumors, and gross 
vascular involvement. A significant lower survival rate was 
observed in patients with bile duct cancer (n = 19) than in 
those with HCC or epithelioid hemangioendothelioma (n 
= 8). Careful patient selection and effective adjuvant anti-
cancer therapy are needed to improve the results of 0 L T for 
primary liver malignancy. 
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The optimal treatment of primary liver malig-
nancy is complete surgical excision of the tumors. Extensive 
subtotal hepatectomy such as right and left trisegmentecto-
mies can now be performed with an operative mortality of less 
than 5% (1-4), We have already reported 1,3 and 5-year sur-
vivals of 69,45 and 32 % after major subtotal hepatectomy for 
primary hepatic malignancy (4). There were. however, many 
other patients who could not be treated with subtotal hepa-
tectomy, either because of extensive hepatic involvement with 
malignant tumor. or because of coexisting advanced liver dis-
ease. These patients had been carefully selected for total hepa-
tectomy and liver replacement (orthotopic liver transplanta-
tion: OL TI. 
Our experience with OL T in the case of pri-
mary hepatic malignancy is summarized here in an attempt to 
examine the factors that influence survival and tumor recur-
rence. 
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Table 1 Histological diagnosis of 115 patients with primary liver 
malignancy 
Histology 
Hepatocellularcarcinoma 
(Non-fibrolamellar) 
(Fibrolamellar) 
Bile duct cancer 
Epithelioidhemangioendothelioma 
Hepatoblastoma 
Cholangiocarcinoma 
Angiosarcoma 
Total 
Numberof patients 
80 
(71) 
( 9) 
19 
8 
4 
2 
2 
115 
Patient materials and methods 
Between January 1980 and December 1988, 1,469 
patients with various advanced liver diseases received orthotopic liver 
transplantation (OLD at the University Health Sciences Center of 
Colorado (1980) and the University Health Center of Pittsburgh (since 
1981). All of these patients were treated with a standard combination 
immunosuppressive therapy of cyclosporine and corticosteroids. 
Azathioprine antilymphocyte globulin or murine monoclonal anti-
body (OKT-3) was used supplementarily in selected patients to con-
trol rejection (5-7). Our surgical techniques have been reported in 
detail elsewhere (8-10). 
One hundred and fifteen (7.4'1;)) of the 1,469 patients 
received OLT for primary hepatobiliary malignancy. In 28 of the 115 
patients, OL T was done to treat hepatic failure. but malignant tumors 
were discovered incidentally at the pathological examination of the 
excised liver ("incidental"malignancy). In the remaining 87 patit:nts, 
the diagnosis of malignancy was established or strongly suspected 
before OLT. Total rather than subtotal hepatectomy was performed 
because of co-exlsting advanced liver disease in 34 patients (malig-
nancy in advanced liver disease), and because of extensive tumor in-
volvement no longer accessible to subtotal hepatectomy in 53 patients 
("unresectable" tumor). 
The histological diagnosis established in I 15 pri-
mary hepatobiliary malignant tumors are listed in Table J. TIlere were 
80 hepatocellular carcinomas (HCe), 19 bile duct cancers (BD Cal, R 
epithelioid hemangioendotheliomas (EHEl. 4 hepatoblastomas 
(HBL), 2 cholangiocarcinomas, and 2 anglOsarcomas. Nine of the 80 
llepatocellular carcinomas were of the librolamellar type. 
Non-cancerous advanced liver di~ease coexisted in 
62 out of J 15 patients wah primary hepatobiJiary malignancy. as 
shown in Table 2. Forty-four of the ~o patlents with HCC had underly-
ing advanced cirrhosis of vanous etIologies. mcluding 22 patients with 
hepatitis B surface antigen (HBsAg). Sixteen elf the 19 bile duct 
cancers developed in advanced primary \c1erosing cholangItis. One 
patient had both blle duct cancer and metastatic (;arcmoid tumor. 
All patients were followed up tor :l period ranging 
from b months to l) vears. with a mean of::5 months. Survlval rates 
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Fig. 1 Survival curves of patients with primary liver malignancy 
(n= 115) and non-malignant diseases (n = 1354) in the period 
1980-1988 
Table 2 Coexisting liver disease with various primary Iivercancers 
Diagnosis Numberofpatients 
Hepatocell ular carcinoma ( n on-fib rolamellar) 
Cirrhosis: 
hepatitis B 22 
non-A, non-B 2 
alcoholic 2 
autoimmune 1 
cryptogenic 5 
hemochromatosis 2 
tyrosinemia 4 
alfa 1 anti-trypsin deficiency 1 
biliary atresia 2 
Neville'sdisease 1 
familialcholestasis 1 
Hepatocellu lar carcinoma (fibrolamellar) 
Cirrhosis: 
cryptogenic 
Bileductcancer 
sclerosing cholangitis 
metastatic carci no i d 
Hepatoblastoma 
biliary atresia 
Total 
16 
1 
18 
62 
~ble 3 Cumulative survival rates in primary liver cancer 
Primary liver cancer Survival rates (%) 
1 year 3year 5year 
Hepatocellular carcinoma (n =80) 
Non-fibrolamellar (n = 71) 64 45 45 
Fibrolamellar (n=9) 89 46 46 
Non-fibrolamellar 
Tumor size <;" em (n=28) 77 '68 68 
Non-fibrolamellar 
B' Tumor size ~;" cm (n=43) 51 25 25 
lie duct cancer (n = 19) 24 24 0 Eplth I" . 
e IOldhemangioendothelioma 88 73 48 (n=8) 
6~patoblastoma (n =4) 25 0 
A olanglOCarcinoma (n = 2) 50 0 ~oma (n=2) 0 
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Fig. 2 2. Survival curves of various types of primary liver malig-
nancy: hepatocellular carcinoma (H CC, n = 80), bile duct cancer 
(SO Cal (n=19), epithelioid hemangioendothelioma (EHE) (n=8) 
and others: hepatoblastoma (n=4), cholangiocarcinoma (n=2) 
and angiosarcoma (n=2) 
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Fig,3 Survival curves offibrolamellar HCC (n = 9) and non-fi-
brolamellar HCC with tumor ~ 5 cm (n=43), 
were calculated by the method of Kaplan-Meier. Statistical compari-
sons were made by the method of Mantel-Cox and by the Chi-squared 
test. The difference was considered significant when the p value was 
less than 0.05, 
Results 
Survival 
The survival rates after 0 L T of the 115 patients 
with primary liver malignancy and the 1,354 patients without it 
were compared, and are shown in Fig. 1. One-, 3- and 5-year 
survival rates of the former were 64%, 37% and 37%, and 
those of the latter were 73, 68, and 65 %, respectively, The sur-
vival rates of patients with primary hepatic malignancy were 
significantly lower than those of patients with no malignancy 
(p < 0.001). 
Survival rates of the 115 patients with primary 
hepatic malignancy were stratified in accordance with the his-
tological diagnosis of the tumors, and are compared in Table 3 
and Fig, 2, Survival of patients with epithelioid hemangioen-
dothelioma (ERE) seemed to be better than that of patients 
with hepatocellular carcinoma (HCC), but the difference was 
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H: non-librolamellar hepatocellular carcinoma 
F: fibrolamellar hepatocellular carcinoma 
D: bile duct cancer 
E: epithelioid hemangioendothelioma 
B: hepatoblastoma 
A: angiosarcoma 
C: cholangiocarcinoma 
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Fig. 4 Timing of recurrence in pri-
mary hepatic malig nancy 
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(MONTH AFTER OL TX) 
Table 4 Survival rate and various factors in non-fibrolamellar hepa-
tocellularcarcinoma 
Factor Mean su rvival Numberof patients 
time(months) OeathslTotal % 
mean ± SE 
Tumorsize 
< 5 cm (n=33) 55±8* 13/33 39 
~ 5 cm (n=38) 24±6 20 138 56 
Tumornumber 
single (n=14) 81± 11 * 2/14 14 
multiple (n=57) 34±6 31/57 56 
Grossvascularinvasion 
(+)(n=16) 18±6 12/16 75 
(-)(n=55) 53±7* 22/55 42 
Lymph node metastasis 
(+)(n= 7) 10±2 4/7 57 
(-)(n=64) 48±6* 30/64 48 
*The difference is statistically significant (p < 0.05) 
not statistically significant (p = 0.36). Survival of patients 
with bile duct cancer (BD Cal was significantly lower than that 
of patients with ERE (p < 0.005) or HCC (p < 0.05). 
Survival rates of 80 patients with HCC were 
further analyzed in accordance with the histopathological 
findings. The survival of 9 patients with fibrolamellar variant 
was not significantly better than that of 71 patients with non-li-
Table 5 Initial and ultimate site of recurrence in primary liver cancer 
Site Diagnosis 
brolamellar hepatoma (p = 03225) (Table 3). However, when 
tumors less than 5 cm in the greatest diameter were excluded, 
survival of patients with fibrolamellar variant was signifi-
cantly better than that of those with non-fibrolamellar hepa-
toma (p < 0.05) (Fig. 3, Table 3). The prognostic influence of 
other histopathological findings, such as the size and number 
of malignant lesions, gross vascular invasion of tumor and re-
gionallymph node metastasis, was examined in the 71 patients 
with non-fibrolamellar hepatoma, and expressed in terms of 
mean survival time (Table 4). Small tumors less than 5 cm in 
the greatest diameter, and single lesions were statistically sig-
nificant good prognostic factors (p < 0.01, P < 0.005, respec-
tively). On the other hand, the presence of gross vascular inva-
sion and regional node metastasis were significantly 
prognostic pathological findings (p < 0.05 and p < 0.05, re-. 
spectively). 
Tumor recurrence 
Incidence, timing and location 
Recurrence of original hepatic malignancy 
was confirmed in 45 of the 115 patients after OL T. Timing of 
recurrence is shown in Fig. 4. Tumor recurrence was diag~ . 
nosed within 3 months after OLT in 12 patients. These very 
early recurrences were most likely due to residual tumors, 
which had not been properly removed by total hepatectomy, . 
or not detected before OLT despite thorough investigation·ror . 
distant metastasis. These very early recurrences were seen in 4. 
patients with BD Ca, 3 patients with hepatocellular carci- . 
Initial (Ultimate) 
HCC BOCa EHE HBL AS CC 
pts (pts) pts (pts) pts (pts) pts (pts) pts (pts) pts (pts) 
liver 9 (16) 2(4) 1 (3) 0(0) o (1) 1 (1) 
Lung 9 (11) 1 (3) 0(3) 1 (1) 1 (1) 0(1) 
Intra-abdominal 
(extrahepatiC) 4(6) 3(5) 0(0) 0(0) 1 (1) 0(0) 
Bone 4(6) 3(3) 2(2) 0(0) 0(1) 0(0) 
Brain OJ 1) 1 (1) 0(0) 0(0) 0(0) 0(0) 
Skin 0(0) 1 (1) 0(0) 0(0) 0(0) 0(0) 
Mediastinum 0(0) 0(0) 1( 1 ) 0(0) 0(0) 0(0) 
Total 26(40) 11 (17) 4(9) 1 (1) 2 (4) 1 (2) 
• HCC: hepatocellular carcinoma, SO Ca: bile duct cancer, EHE: epithelioid hemangioendothelioma. HBL: hepatoblastoma, AS: angiosar-
coma. CC: cholanglocarcinoma 
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Table 6 The influence of histopathological factors on tumor recur-
rence 
Factor Numberof patients 
Recurrence/Total Rate (0/0) 
Statistics 
(Pvalue) 
1 ) Non-tlbrolameliar 23/62 
fibrolamellar 3/8 
non-fibrolamella: 
tumor size 2: 5 cm 21/34 
fibrolamellar, 
tumor size C::. 5 em 3/8 
2) Non-flbrolamellar 
tumor size 5cm 2!28 
tumor size .:.c 5cm 2:/34 
3) Non-fibrolameliar 
single tumor 1/15 
multiple tumor 22/47 
4) Non-fibrolamellar 
gross vascular Invasion 8f 11 
no vascular Invasion 15/51 
5) NGn-fibrolamellar 
lymph node metastasis (+) 3/4 
lymph node metastasis H 20/58 
N.S.· : not Significant 
Table 7 Cause and timing of death 
37 N.S.' 
38 
62 N.S.' 
38 
20 0.0005 
62 
7 
47 
73 
29 
75 
34 
< 0.05 
< 0.05 
N.S.' 
noma. :2 patients with angiosarcoma. :2 patients with 
epithelioid hemangioendothelioma. and I patient with hepa-
toblastoma. 
By One year after OL T an auditional 
25 patients developed tumor recurrences: these included 
I X palie11ls with HCC and 7 with bile duct cancer. Between I 
~lIld 2 y-:ars ,,!ler OL T. tulllor n:currence, were dlagJllls\,;u III 
4 patients with hepatocellular carcinoma (:2 each of non-fibro-
lamellar and fihrolamellar. hepatocellular carcinoma). 
::: patients with epi-thelioid hemangioendothelioma. and I 
with chol~\I1gio-:ar-:inol11a. After :2 years another patient with 
l"ihroLtmellar hepatocellular carcinoma developed recurrent 
IUIllUr (FIg. 4). 
The first location or recurrence and the organs 
ultimately involved by tumors were examined in the 45 
patients according to the histological diagnosis of malignancy, 
and are summarized in Table 5, The transplated liver was the 
most common site of recurrence, followed by the lung. 
Factors influencing tUI1/O!' recurrence 
Histopathological findings which might in-
fluence the tumor recurrence were examined in the 70 patients 
with HCC. who were rendered tumor-free at the time of OLT 
and who survived more than 3 months (Table 6), Three (38 %) 
of the 8 patients with fibrolamellar hepatoma and 23 (37'1u) of 
the 62 patients with non-fibrolamellar hepatoma developed 
tumor recurrence. When the tumors of less than 5 em in the 
greatest diameter were excluded. 21 out of 33 patients (64%) 
Time D i a g nos i san d n u m b e r 0 f pat i e n t s 
Causeofdeath 
< 3months 
Hepato-
cellular 
carcinoma 
Operative death 1 
Graftfailure (a) 5 
Infection 3 
Lymphoma(b) 
(total) 
3-12months 
Graftfailure (a) 
Hepatitis B 
Infection 
Malignancy 
(total) 
> 12months 
Graftfailure (a) 
Hepatitis B 
Lymphoma(b) 
Malignancy 
Others (c) 
10 
2 
3(2) • 
2 
9 
16 
1 
8 
Bile Epithelioid-
duct hemangio-
cancer endothelioma 
0 0 
2 0 
0 0 
0 0 
2 0 
3 (2)' a 
a a 
0 a 
4 0 
7 0 
0 
0 0 
0 0 
4 2 
0 0 
-------------------------------------------------------------(total) 12 4 3 
38 13 3 
Others (d) 
o 
2 (1)' 
1 (1) * 
o 
3 
o 
o 
o 
1 
o 
a 
o 
1 
o 
5 
(al: Gra.ftfailure due to technical failure, poor graft orrejection; (b) : Lymphoproliferative disorders; (c): Myocardial infarction; (d): Hepato-
blastoma (4), Cholangiocarcinoma (2), Angiosarcoma (2) ;' : Died with malignancy 
: .,! 
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Table 8 Long-term survival 
OLH Survival Oiagnosis Comments 
(months) 
3-4 years 
812 36 BOCa early cancer in PSC' 
813 36 BOCa earlycancerin PSC 
789 37 EHE 
777 38 EHE 
712 39 FL-HCC size:4cm 
749 39 HCC size:4cm 
603 45 EHE 
4--5 years 
475 54 HCC size:2cm 
483 54 HCC size:2cm 
> 5 years 
400 61 HCC size:2cm 
379 63 HCC size:7cm 
351 65 HCC size: 12cm 
356 65 HCC size:2cm 
288 70 HCC size:5cm 
316 70 EHE 
231 82 FL-HCC size: 19cm 
222 88 HCC size:2cm 
206 91 HCC size:2cm 
198 94 HCC size:2cm 
194 95 FL-HCC size: 15cm 
BO Ca:bile duct cancer, EHE: epithelioid hemangioendothelioma, 
FL-HCC:fibrolameliarhepatoceliularcarcinoma, HCC: non-
fibrolamellarhepatocellular carcinoma, • PSC: pri mary sclerosi ng 
cholangitis . 
with hepatocellular carcinoma, but none of 8 patients with fi-
brolamellar hepatocellular carcinoma developed recurrence 
within a year after OL T. The differences was statistically sig-
nificant (p < 0.0001). 
Among the 62 patients with non-tibrolamellar 
hepatoma, the tumors ofless than 5 em in the greatest diameter 
recurred significantly less frequently (2 of 28, or 71~1,1) than 
those of larger tumors (21 of 34. or 62%) (p < 0.001). The 
number of gross malignant lesions also influenced the recur-
rence rate: only one (7 %,) of the 15 single lesions recurred. in 
contrast to 22 (47 'X,) of 47 multiple lesions (p < 0.005). The 
tumors with gross vascular invasion (~ of 11, or 73 '%) recurred 
more frequently than those without gross vascular invasion 
(15 of 51, or 29°/.,) (p < 0.05). The tumors with nodal 
metastases (3 of 4, or 75 '%) also recurred more frequently than 
those without nodal metastasis CO of 58. or 34 O{,), but the 
difference was not statistically significant (p = O.3035l. 
'vialignant tumors other than hepatocel1ular carcinoma were 
too few for analysis. 
~'vfail1 cause lildeath 
Fifty-nine of the liS patients died during fol-
low-up. The main causes of death are shown in Table 7. to-
gether with the time ot death and histological dIagnOSIs. The 
most common cause of death within 3 months after OL Twas 
graft failure due to either technical failure. poor quality Df the 
graft. l>f rejection. Two patients died with residual malig-
nancy, which. however. was not considered the direct cause of 
tleath. No patient died ill' malignancy during this period. In 
contrast. the most common cause of death after 3 months was 
ihe i'ccurrence \11' original malignancy 1::'9 i)f -'1-4. \lr 00 0 (,), 
These lumor-relaled ueaths contnbuted to the 'lgmficantly 
I. Yokoyama, S. Todo, S. Iwatsuki, E. Starzl 
----lower survival of patients with malignancy as compared With 
that of patients with no malignancy (Fig. I). 
Lung-term survivors 
A total of 20 patients survived more than 3 
years after OL T in the presellce of primary liver m~tlignancy 
(Table 8). Fourteen patients had hepatocellular carcmoma, of I 
whom 3 had fibrolamellar variant. and 9 solitary small (less r 
than 5 cm) lesiolls. Four of the 20 3-year survivors had 
epithelioid hemangioendothelioma, and :2 patients had unex- ~ 
pected early bile duct cancer in advanced primary scleroSing l 
cholangitis. 
Discussion 
The results of total hepatectomy and liver re-
placement (orthotopic liver transplantation: OL T) for malig-
nancy are mixed ( 11-16 J. Although the mere presence of pri-
mary hepatic malignancy does not necessarily rule out the 
possibility of long-term survival, tumor recurrence after OLT 
is the rule rather than the exception. 
Our data presented here indicate that small 
(less than 5 cm), single lesions of hepatocellular carcinoma 
with no vascular invasion, developed in advanced cirrhosis, 
can be very effectively treated by OLT. The long-term survival 
rates of these patients were as good as those without hepatic 
malignancy. Among large hepatic malignancies which cannot 
be resected by subtotal hepatectomy, the tibrolamellar variant 
of hepatocellular carcinoma and epithelioid hemangioen-
dothelioma showed a favorable prognosis after OL T as com-
pared with other types of primary hepatic malignancy. 
However, the results after OL T for large. multi-
ple lesions of non-tibrolamellar hepatocellular carcinoma 
were quite discouraging, particularly when vascular and/or 
nodal invasions were present. In these patients tumor recur· 
renee was usually confirmed within a year atter OL T. and sur-
vival thereafter was limited to several months. 
There are three main causes for treatment 
failures (tumor recurrence), which must be overcome for 
further improvement. TIle first cause is an error in the pretrans-
plant evaluation of candidates. Despite a carct1.li search for ex-
trahepatic metastases with CT scan. M R I and various radio-
graphic studies. minute melastatic lesions can easiJy be 
missed. The second C~luse is enhanced tumOl' g:rowth under im-
munosupprcssive therapy. Tumor douhling timc in recurrent 
hepatocellular C<lIT1I10ma \Vas measured III l) llf llur patients 
with recurrence in the liver after OL T, ~lI1d was i'()und to be 
considerablv shortened- :26.:2 ± Il.K davs Imean ± SEM) in 
those patie~ts on cyclosponne-steroid tI~erapy. as compared 
with the average uf 102-195 davs Without immunosuppres-
sion rep0rLl:U III till: literature \ i 7 -1 ')). 
The third cause is a lack Ill' elfcctivc ;.lllti-cal1l:cr 
therapy following surgical I'emovai '.lf hepatie malignanq. 
Indeed. many rHltients remained chemical Iv ~llld ral:'iographi-
caHy tumor-free for several months after () LT. 
This lucid interv;d proVided hv iOlal hepa-
tectomy ~ll1li replacement must he sufficient I'or sume effeclive 
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anticancer therapy to eliminate microscopiL' nests of malig-
n~ll1l cells. 
It was sometimes tempting to conclude during 
the review 01' our experience (I L IS) and that of others (12-
I·'+;' that liver transplantation for regionally advanced primary 
mal ignaney is a futilc effort. However, it is a fact that arrest and 
contI''') ,iI' lite' maiignal1l pruees~ Uy":l y..:ar~ has been W.;(;Olll-
plished under some of the least likely circumstances - as with 
patic:nts who had distant mctastasis at the time of transpLlllta-
tion from epithelioid hemangioendothelioma. and patients 
whu had large. multiple lesions of l1on-fibrolamellar hepa-
toma. Although somc or the histopathological factors in-
tluencing the outcome have been identified. many other fac-
tors remain to be discovered. and more effective anti-cancer 
ther~lpy to be developed for liver transplantation to establish a 
firm role in the treatment of hepatic malignancy. 
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